Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
The discovery of IDO1 and HDAC1 dual inhibitors may provide a novel strategy for cancer treatment by taking advantages of both immunotherapeutic and epigenetic drugs. In this paper, saprorthoquinone (<b>1</b>) and 13 of its analogues from <i>Salvia prionitis</i> Hance were in...
Main Authors: | Yang Lin, Heyanhao Zhang, Tong Niu, Mei-Lin Tang, Jun Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/19/4494 |
Similar Items
-
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
by: Kai Tang, et al.
Published: (2021-04-01) -
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
by: Takefumi Komiya, et al.
Published: (2018-10-01) -
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
by: Asha Nayak-Kapoor, et al.
Published: (2018-06-01) -
Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy
by: Ning Deng, et al.
Published: (2021-02-01) -
Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
by: Lingfei Wu, et al.
Published: (2012-08-01)